Core Viewpoint - InspireMD, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference, highlighting its focus on the CGuard Prime carotid stent system aimed at stroke prevention [1]. Company Overview - InspireMD, Inc. utilizes proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, aiming for excellent acute results and long-term stroke-free outcomes [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2].

Core Viewpoint - InspireMD, Inc. is set to release its fourth quarter and full year 2025 financial results on March 18, 2026, and will host a conference call to discuss these results and recent highlights [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and full year 2025 will be announced on March 18, 2026 [1]. - A conference call and webcast will take place at 8:30 a.m. Eastern Time on the same day to discuss the financial results [1]. Group 2: Company Overview - InspireMD, Inc. develops the CGuard Prime carotid stent system aimed at preventing strokes [1]. - The company utilizes proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, focusing on acute results and long-term stroke-free outcomes [3]. - InspireMD's common stock is traded on Nasdaq under the ticker symbol NSPR [3]. Group 3: Investor Information - A live audio webcast and an archive of the recording will be available on InspireMD's corporate website [2]. - Interested participants are encouraged to register more than 15 minutes before the start of the call [2].

Core Viewpoint - InspireMD, Inc. is set to participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3rd, 2025, highlighting its focus on carotid stenting technology aimed at stroke prevention [1]. Company Overview - InspireMD, Inc. develops the CGuard® Prime carotid stent system, utilizing proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting [2]. - The company aims to deliver exceptional acute results and long-term outcomes that are stroke-free, emphasizing its commitment to innovation in the healthcare sector [2]. - InspireMD's common stock is traded on Nasdaq under the ticker symbol NSPR, and the company actively shares important investor information on its website [2].

Core Insights - InspireMD, Inc. has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategy during a critical phase for the company [1][2] Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [5] Leadership Appointment - Dr. Soukas brings extensive experience in vascular intervention, serving as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University, where he founded the Vascular and Endovascular Medicine Fellowship Program [2][3] - His background includes being a principal investigator in over 24 carotid stenting trials and more than 150 endovascular trials, along with delivering over 300 invited lectures and publishing numerous peer-reviewed papers [3] Strategic Vision - Dr. Soukas expressed his commitment to guiding InspireMD in clinical and medical topics, aiming to enhance awareness of the CGuard Prime stent platform and improve patient care through collaboration with clinical partners [4]

Core Insights - InspireMD, Inc. will release its third quarter 2025 financial results on November 4, 2025, and will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss these results and recent highlights [1]. Company Overview - InspireMD, Inc. is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes [1]. - The company utilizes its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [2]. Investor Information - Interested parties can access the live earnings call via telephone or through a live webinar on InspireMD's website, with a replay available shortly after the call [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR [2].

Core Viewpoint - InspireMD, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, highlighting its focus on the CGuard® Prime carotid stent system for stroke prevention [1] Company Overview - InspireMD, Inc. aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, emphasizing superior acute results and long-term stroke-free outcomes [2] - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2]

Company Overview - InspireMD, Inc. is a developer of the CGuard Prime carotid stent system aimed at preventing strokes [1] - The company utilizes proprietary MicroNet™ mesh technology to enhance the effectiveness of its carotid stenting products [2] Financial Results Announcement - InspireMD will release its second quarter 2025 financial results on August 5, 2025 [1] - A conference call and webcast will be held at 8:30 a.m. Eastern Time to discuss the financial results and recent highlights [1] Access to Earnings Call - Interested parties can access the live earnings call via telephone or through a webcast on InspireMD's website [2] - A replay of the webinar will be available shortly after the call and archived on the company's website [2]